Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk.

Lancet. 2002 Nov 23;360(9346):1623-30.


Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Jackevicius CA, Mamdani M, Tu JV.

JAMA. 2002 Jul 24-31;288(4):462-7.


Long-term persistence in use of statin therapy in elderly patients.

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J.

JAMA. 2002 Jul 24-31;288(4):455-61.


Low prevalence of lipid lowering drug use in older men with established coronary heart disease.

Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A.

Heart. 2002 Jul;88(1):25-9.


Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction.

Boucher JM, Racine N, Thanh TH, Rahme E, Brophy J, LeLorier J, Théroux P; Quebec Acute Coronary Care Working Group.

CMAJ. 2001 May 1;164(9):1285-90.


Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

LaRosa JC, He J, Vupputuri S.

JAMA. 1999 Dec 22-29;282(24):2340-6.


Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction.

Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA.

Can J Cardiol. 1999 Nov;15(11):1277-82.


Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.

Flaker GC, Warnica JW, Sacks FM, Moyé LA, Davis BR, Rouleau JL, Webel RR, Pfeffer MA, Braunwald E.

J Am Coll Cardiol. 1999 Jul;34(1):106-12.


Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.

N Engl J Med. 1998 Nov 5;339(19):1349-57.


Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines.

Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS.

Circulation. 1998 Sep 1;98(9):851-5.


Prediction of coronary heart disease using risk factor categories.

Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB.

Circulation. 1998 May 12;97(18):1837-47.


The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.

Post Coronary Artery Bypass Graft Trial Investigators.

N Engl J Med. 1997 Jan 16;336(3):153-62. Erratum in: N Engl J Med 1997 Dec 18;337(25):1859.


The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E.

N Engl J Med. 1996 Oct 3;335(14):1001-9.


A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators.

Rouleau JL, Moyé LA, Pfeffer MA, Arnold JM, Bernstein V, Cuddy TE, Dagenais GR, Geltman EM, Goldman S, Gordon D, et al.

N Engl J Med. 1993 Mar 18;328(11):779-84.


Coronary artery surgery in women compared with men: analysis of coronary risk factors and in-hospital mortality in a single centre.

Barbir M, Lazem F, Ilsley C, Mitchell A, Khaghani A, Yacoub M.

Br Heart J. 1994 May;71(5):408-12.


Supplemental Content

Support Center